These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31203401)

  • 1. Replication and extension of a model predicting response to psilocybin.
    Russ SL; Carhart-Harris RL; Maruyama G; Elliott MS
    Psychopharmacology (Berl); 2019 Nov; 236(11):3221-3230. PubMed ID: 31203401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
    Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
    J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
    Barrett FS; Johnson MW; Griffiths RR
    J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.
    Carbonaro TM; Johnson MW; Hurwitz E; Griffiths RR
    Psychopharmacology (Berl); 2018 Feb; 235(2):521-534. PubMed ID: 29116367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
    Stenbæk DS; Madsen MK; Ozenne B; Kristiansen S; Burmester D; Erritzoe D; Knudsen GM; Fisher PM
    J Psychopharmacol; 2021 Apr; 35(4):459-468. PubMed ID: 33501857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response.
    Calder AE; Rausch B; Liechti ME; Holze F; Hasler G
    J Psychopharmacol; 2024 Oct; 38(10):873-886. PubMed ID: 39302087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psilocybin occasioned mystical-type experiences.
    James E; Robertshaw TL; Hoskins M; Sessa B
    Hum Psychopharmacol; 2020 Sep; 35(5):e2742. PubMed ID: 32573835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland.
    Kangaslampi S; Hausen A; Rauteenmaa T
    J Psychoactive Drugs; 2020; 52(4):309-318. PubMed ID: 32511073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.
    Griffiths R; Richards W; Johnson M; McCann U; Jesse R
    J Psychopharmacol; 2008 Aug; 22(6):621-32. PubMed ID: 18593735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies.
    Stocker K; Hartmann M; Ley L; Becker AM; Holze F; Liechti ME
    J Psychopharmacol; 2024 Jan; 38(1):80-100. PubMed ID: 37905369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy.
    Hendricks PS
    Int Rev Psychiatry; 2018 Aug; 30(4):331-342. PubMed ID: 30260256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.
    Davis AK; Barrett FS; So S; Gukasyan N; Swift TC; Griffiths RR
    J Psychopharmacol; 2021 Apr; 35(4):437-446. PubMed ID: 33427007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
    Garcia-Romeu A; Griffiths RR; Johnson MW
    Curr Drug Abuse Rev; 2014; 7(3):157-64. PubMed ID: 25563443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches.
    Garcia-Romeu A; Barrett FS; Carbonaro TM; Johnson MW; Griffiths RR
    J Psychopharmacol; 2021 Apr; 35(4):353-361. PubMed ID: 33611977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving.
    Sweat NW; Bates LW; Hendricks PS
    J Psychoactive Drugs; 2016; 48(5):344-350. PubMed ID: 27719438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
    Griffiths RR; Johnson MW; Richards WA; Richards BD; McCann U; Jesse R
    Psychopharmacology (Berl); 2011 Dec; 218(4):649-65. PubMed ID: 21674151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-response relationships of psilocybin-induced subjective experiences in humans.
    Hirschfeld T; Schmidt TT
    J Psychopharmacol; 2021 Apr; 35(4):384-397. PubMed ID: 33663259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.
    Barrett FS; Griffiths RR
    Curr Top Behav Neurosci; 2018; 36():393-430. PubMed ID: 28401522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a French Version of the Mystical Experience Questionnaire with Retrospective Reports of the Most Significant Psychedelic Experience among French Users.
    Fauvel B; Kangaslampi S; Strika-Bruneau L; Roméo B; Piolino P
    J Psychoactive Drugs; 2023; 55(2):170-179. PubMed ID: 35384730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.